期刊
CLINICAL BIOCHEMISTRY
卷 45, 期 7-8, 页码 519-524出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.clinbiochem.2011.12.030
关键词
Myocardial infarction; Biomarkers; Major adverse cardiac events (MACE); Cardiovascular risk; Prognosis Immunoassay; Acute coronary syndrome; Ischemia; Pregnancy Associated Plasma Protein A (PAPP-A); IGFBP-4 fragments
Objectives: Pregnancy Associated Plasma Protein A (PAPP-A)-derived N- and C-terminal fragments of ICF-binding protein-4 (NT- and CT-IGFBP-4) released from vulnerable atherosclerotic plaques are proposed to be used for cardiovascular risk assessment. Design and methods: NT- and CT-IGFBP-4 were measured by novel immunoassays in EDTA-plasma of 180 patients admitted to the emergency department with symptoms of myocardial ischemia but without ST-segment elevation. Six-month incidence of major adverse cardiac events (MACE), including myocardial infarction, cardiac death, percutaneous coronary interventions, and coronary artery bypass grafting was recorded. Results: Sixteen patients met the endpoint. NT- and CT-IGFBP-4 were strong predictors of MACE: area under ROC curve (AUC) 0.856 and 0.809, respectively. NT-IGFBP-4 concentrations >= 2141 mu g/L and CT-IGFBP-4 concentrations >= 124 mu g/L were associated with increased risk of future MACE: adjusted hazard ratio 13.79 and 7.93, respectively. Conclusions: IGFBP-4 fragments can be utilized as biomarkers for MACE prediction in patients with suspected myocardial ischemia. (C) 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据